Withdrawn 36th Lorne Cancer Conference 2024

Comprehensive analysis of immune cell multi-omics in cancer patients who are experiencing immune-related adverse events (NOT ATTENDING) (#242)

Dmitrii Shek 1 , Bo Gao 2 , Joey Lai 3 , Brian Gloss 3 , Adnan Nagrial 4 , Matteo S Carlino 4 , Ines Pires da Silva 2 , Jacob George 3 , Scott A Read 1 , Golo Ahlenstiel 1
  1. Western Sydney University, Blacktown, NSW, Australia
  2. Blacktown Hospital, Blacktown, NSW, Australia
  3. Westmead Institute for Medical Research, Sydney, NSW, Australia
  4. Westmead Hospital, Sydney, NSW, Australia

Background. The clinical efficacy of immune-checkpoint inhibitors is complicated by the risk for immune-related adverse events (irAEs) that can involve any organ systems. To date, (1) we cannot predict irAE risk reliably at patient level and (2) irAEs remain a diagnosis of exclusion as there are no specific clinical or biological markers. 

Methods. This pilot trial was conducted as part of a prospective multicenter cohort study (NCT04631731). PBMCs from n=71 patients were collected from both pre-treatment and after 6-8 weeks post-ICI commencement. Samples were further utilised for RNA sequencing and Chromium 3’ analysis (10x Genomics). 

Results. The median age was 67 years old with the 78% (n=56) of Caucasian origin. N=21 patients experienced irAEs. Firstly, a differential analysis established a set of genes which were significantly (FDR<0.01) dysregulated between patients with (group A) and without irAEs (group B) and were mostly related to cell cycle and regulation. Notably, phospholipase D signaling pathway was exclusively upregulated in group A and is known to be linked to B cell expansion. Secondly, a cell enrichment analysis within the group A revealed a significant increase of CD4+ and CD8+ T central memory (Tcm) cells upon the toxicity onset as compared to baseline stage. Finally, we sequenced CD45+ cells from n=4 patients from group A and n=4 from group B at both pre- and post-treatment stages. The unsupervised clustering established 17 different clusters in our single cell dataset with cluster 11 was unique only to patients from group A. The differential analysis established that a set of n=62 genes was significantly upregulated in cluster 11. Functional annotation established that B cell activation and proliferation pathways were enriched by those genes further stressing B cells’ role in irAEs development.

Conclusions. Our real-world cohort study established significant molecular and cellular differences between patients with and without irAEs. Further research in larger cohorts is imperative to validate the established findings and to elucidate the precise mechanisms contributing to the development of irAEs.